A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).

November 24, 2025 updated by: Jaime Marino
Cardiovascular disease is the leading cause of mortality globally. In India cardiovascular disease leads to death a decade earlier than in western countries. In the past 20 years awareness and classic risk factors and statins have been the main improvements. However, all these factors have not decreased the cardiovascular disease burden. One reason may be because all of the current assessments for cardiac risk are correlants to disease and none are specific to cardiac myocyte status.

Study Overview

Status

Suspended

Detailed Description

Development of high-sensitivity assays for cardiac troponin I (hs-TnI) has enhanced the ability to detect low circulating levels of cardiac troponins, which are often present in individuals with common cardiac conditions and risk factors who have not manifested clinical cardiovascular disease (CVD). Lowering the detection threshold of troponin assays has expanded the potential use of cardiac troponins from a diagnostic tool in the setting of acute coronary syndrome to a biomarker for risk stratification in individuals without known CVD. Detectable levels of cardiac troponins have been associated with increased incidence of coronary heart disease (CHD), heart failure (HF), and cardiovascular mortality in community-based studies.

Traditional cardiovascular risk prediction does not identify everyone who will develop cardiovascular disease with up to 50% of individuals having none or only one risk factor at the time of diagnosis. Although traditional risk estimations perform moderately well, there remain significant limitations in their use in the prevention of cardiovascular disease especially at an individual level. At an individual level, the clinician not only needs to correctly identify those at increased risk, but also weigh up the importance of each risk factor and determine who needs medical therapy in addition to lifestyle advice Many risk estimation systems in existence are based on a core set of cardiovascular risk factors and based on participants either selected randomly from the general population or those attending their general practitioner. All these risk scoring systems show a good level of discrimination, for cardiovascular events, with the area under the receiving operator curve ranging from 0.73 to 0.82. However, adopting these risk scoring systems to guide current clinical practice has limitations. First, most of these scoring systems, except QRISK1 and QRISK2 have been developed from old prospective cohorts with participants recruited in the 1980's and 1990's Second, applying risk estimation scores to regions with different rates of baseline rates of cardiovascular disease will lead to either under- or over-estimation of risk: a result of mis-calibration. Third, the value of incorporating new risk factors including biomarkers such as high-sensitivity C reactive protein has been disappointing in improving discrimination, with age and sex alone contributing to 0.70 of the area under the receiver operating curve statistic. None of these risk estimation scores, to date, incorporate a direct measure of cardiac injury such as cardiac troponin and its potential role in guiding primary prevention in a contemporaneous population remains uncertain.

Study Type

Observational

Enrollment (Estimated)

300000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangalore, India
        • Apollo Hospitals
      • Chennai, India
        • Apollo Hospitals
      • Hyderabad, India
        • Apollo Hospitals
      • Kolkata, India
        • Apollo Hospitals
      • Mumbai, India
        • Apollo Hospitals
      • New Delhi, India
        • Apollo Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All subjects undergoing health checks at Apollo Group of hospitals in Hyderabad, Chennai, Bangalore, Mumbai, Kolkata and New Delhi.

Description

Inclusion Criteria:

  1. All men and women above the age of 18 years
  2. Lipid profiles ordered
  3. HbA1c ordered
  4. Creatinine ordered

Exclusion Criteria:

1. Non-consenting subjects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the hsTnI categorical CVD risk model with the Apollo Healthcare system in subjects attending the Preventive Health Checkups.
Time Frame: Through study completion, an average of 1 year
Number of individuals classified as high, moderate, low risk based on the pre-defined cut-offs of high-sensitivity troponin I.
Through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implementation of recommendation for the low, moderate and high risk in subjects and monitoring the outcome in the cardiac registry database.
Time Frame: Through study completion, an average of 1 year
Number of individuals that follows the cardiovascular risk stratification algorithm: lifestyle consultation, treatment of underlying conditions such as hypertension, diabetes, hyperlipidemia as well as ECG, stress test echocardiography recommendations and number of individuals experiencing the adverse cardiovascular outcomes per cardiovascular risk category.
Through study completion, an average of 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optimize the use of hsTnI risk categories by clinicians
Time Frame: Through study completion, an average of 1 year
Estimate the longitudinal changes of the number of clinicians that recommend the following based on the cardiovascular risk stratification algorithm: lifestyle consultation, treatment of underlying conditions such as hypertension, diabetes, hyperlipidemia as well as ECG, stress test and echocardiography recommendations.
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Pratap C Reddy, MD, Apollo Hopsitals
  • Principal Investigator: Hari Prasad, MD, Apollo Hospitals Enterprise Limited
  • Principal Investigator: Abraham Oomman, MD, Apollo Hospitals Enterprise Limited
  • Principal Investigator: Padma Madala, MD, Apollo Hospitals Enterprise Limited
  • Principal Investigator: Jaganathan Sickan, MD, Abbott
  • Principal Investigator: Agim Beshiri, MD, Abbott

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 12, 2019

Primary Completion (Estimated)

September 12, 2029

Study Completion (Estimated)

September 12, 2030

Study Registration Dates

First Submitted

May 12, 2021

First Submitted That Met QC Criteria

May 25, 2021

First Posted (Actual)

May 26, 2021

Study Record Updates

Last Update Posted (Actual)

November 28, 2025

Last Update Submitted That Met QC Criteria

November 24, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACCR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share with other researchers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe